News & Updates

In the subgroup analysis of the phase III FIGARO-DKD trial, the selective nonsteroidal mineralocorticoid receptor antagonist finerenone conferred cardiorenal benefits in Chinese patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). The findings were consistent with that observed in the overall cohort.

In the treatment of moderate-to-severe benign prostatic hyperplasia (BPH) in Singapore, water vapor thermal therapy (WVTT) is more cost effective than medical management (MM) in the first-line setting based on the common willingness-to-pay threshold of SGD 50,000 per quality-adjusted life-years (QALYs), a study has found.

Adding percent free prostate-specific antigen (PSA) to total PSA results in better prediction of clinically significant prostate cancer and fatal prostate cancer in men, reports a study.

Resistance exercise training counters the negative effects of androgen deprivation therapy (ADT) and improves muscle fibre size, as well as capillarization, in patients with prostate cancer, reports a study.

The Erection Hardness Scale (EHS) proves to be reliable in differentiating between predominantly organic and apparently nonorganic erectile dysfunction (ED), reducing the need for further nocturnal penile tumescence and rigidity (NPTR) testing, as reported in a study.

Treatment with five-alpha reductase inhibitors (5αRIs) does not appear to elevate the risk of hospitalization for heart failure (HF), myocardial infarction (MI), stroke, or cardiovascular death among men with benign prostatic hyperplasia (BPH), a study has shown.